Skip to Content
Merck
CN

Y0000709

Oxitropium bromide

European Pharmacopoeia (EP) Reference Standard

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C19H26BrNO4
CAS Number:
Molecular Weight:
412.32
UNSPSC Code:
41116107
NACRES:
NA.24
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

SMILES string

[Br-].[N+]1(C2C3OC3C1CC(C2)OC(=O)C(CO)c4ccccc4)(CC)C

InChI

1S/C19H26NO4.BrH/c1-3-20(2)15-9-13(10-16(20)18-17(15)24-18)23-19(22)14(11-21)12-7-5-4-6-8-12;/h4-8,13-18,21H,3,9-11H2,1-2H3;1H/q+1;/p-1

InChI key

LCELQERNWLBPSY-UHFFFAOYSA-M

grade

pharmaceutical primary standard

API family

oxitropium

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Oxitropium bromide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Regulatory Information

监管及禁止进口产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

C Taube et al.
Respiratory medicine, 97(5), 568-577 (2003-05-09)
The aim of the present study was to assess the reproducibility of changes in forced inspiratory volumes after bronchodilator inhalation. Thirteen patients with chronic obstructive pulmonary disease (COPD) (FEV1, 32-75%pred) and 10 patients with asthma (FEV1, 43-75%pred) inhaled either 200
Efficacy of inhaled anticholinergics and anesthesia in treatment of a patient in status asthmaticus.
Hirokazu Arakawa et al.
The Journal of asthma : official journal of the Association for the Care of Asthma, 39(1), 77-80 (2002-03-09)
Željko Skoko et al.
Journal of the American Chemical Society, 132(40), 14191-14202 (2010-09-24)
The anticholinergic agent oxitropium bromide possesses rich crystal chemistry, most remarkably exhibiting a strong thermosalient effect ("jumping crystal" effect), a mechanical property with potential applications in organic-based actuators. The thermosalient effect, manifested in forceful jumps of up to several centimeters
Hiroshi Kanazawa et al.
Chest, 125(4), 1368-1371 (2004-04-14)
The interaction between chronic hepatitis C virus (HCV) infection and bronchial asthma is of considerable interest. This study was designed to examine whether differences in airway responses to an inhaled anticholinergic agent exist between asthmatic patients with and without active
A Castagnaro et al.
La Radiologia medica, 113(1), 43-55 (2008-03-14)
Airway-wall remodelling may result in reduced airway distensibility in bronchial asthma. This study evaluated the baseline airway calibre and distensibility in asthmatic patients by means of high-resolution computed tomography (HRCT). We studied seven patients (two men, age range 36-69 years)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service